# AET02 variant 1 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                     Placebo     Xanomeline High Dose   Xanomeline Low Dose   All Patients
        MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)            (N=254)   
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event     34 (39.5%)        61 (84.7%)            63 (65.6%)        158 (62.2%) 
      Overall total number of events                                   71               189                    177               437     
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                             
        Total number of patients with at least one adverse event   19 (22.1%)        34 (47.2%)            35 (36.5%)         88 (34.6%) 
        Total number of events                                         37                86                    90                213     
        PRURITUS                                                    8 (9.3%)         26 (36.1%)            23 (24.0%)         57 (22.4%) 
        ERYTHEMA                                                   9 (10.5%)         14 (19.4%)            15 (15.6%)         38 (15.0%) 
        RASH                                                        5 (5.8%)         11 (15.3%)            13 (13.5%)         29 (11.4%) 
        SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)              6 (6.2%)          14 (5.5%)  
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                               
        Total number of patients with at least one adverse event   10 (11.6%)        29 (40.3%)            31 (32.3%)         70 (27.6%) 
        Total number of events                                         20                72                    73                165     
        APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)            23 (24.0%)         50 (19.7%) 
        APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)            13 (13.5%)         30 (11.8%) 
        APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)              9 (9.4%)          21 (8.3%)  
      GASTROINTESTINAL DISORDERS                                                                                                         
        Total number of patients with at least one adverse event    4 (4.7%)         10 (13.9%)             6 (6.2%)          20 (7.9%)  
        Total number of events                                         6                 21                    10                 37     
        VOMITING                                                    3 (3.5%)          6 (8.3%)              4 (4.2%)          13 (5.1%)  
        NAUSEA                                                      3 (3.5%)          6 (8.3%)              3 (3.1%)          12 (4.7%)  
      NERVOUS SYSTEM DISORDERS                                                                                                           
        Total number of patients with at least one adverse event    7 (8.1%)          6 (8.3%)              3 (3.1%)          16 (6.3%)  
        Total number of events                                         8                 9                      4                 21     
        HEADACHE                                                    7 (8.1%)          6 (8.3%)              3 (3.1%)          16 (6.3%)  
      VASCULAR DISORDERS                                                                                                                 
        Total number of patients with at least one adverse event       0              1 (1.4%)                  0              1 (0.4%)  
        Total number of events                                         0                 1                      0                 1      
        WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0              1 (0.4%)  

# AET02 variant 2 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                     Placebo     Xanomeline High Dose   Xanomeline Low Dose   All Patients
        MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)            (N=254)   
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event     34 (39.5%)        61 (84.7%)            63 (65.6%)        158 (62.2%) 
      Overall total number of events                                   71               189                    177               437     
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                             
        Total number of patients with at least one adverse event   19 (22.1%)        34 (47.2%)            35 (36.5%)         88 (34.6%) 
        PRURITUS                                                    8 (9.3%)         26 (36.1%)            23 (24.0%)         57 (22.4%) 
        ERYTHEMA                                                   9 (10.5%)         14 (19.4%)            15 (15.6%)         38 (15.0%) 
        RASH                                                        5 (5.8%)         11 (15.3%)            13 (13.5%)         29 (11.4%) 
        SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)              6 (6.2%)          14 (5.5%)  
        Total number of events                                         37                86                    90                213     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                               
        Total number of patients with at least one adverse event   10 (11.6%)        29 (40.3%)            31 (32.3%)         70 (27.6%) 
        APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)            23 (24.0%)         50 (19.7%) 
        APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)            13 (13.5%)         30 (11.8%) 
        APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)              9 (9.4%)          21 (8.3%)  
        Total number of events                                         20                72                    73                165     
      GASTROINTESTINAL DISORDERS                                                                                                         
        Total number of patients with at least one adverse event    4 (4.7%)         10 (13.9%)             6 (6.2%)          20 (7.9%)  
        VOMITING                                                    3 (3.5%)          6 (8.3%)              4 (4.2%)          13 (5.1%)  
        NAUSEA                                                      3 (3.5%)          6 (8.3%)              3 (3.1%)          12 (4.7%)  
        Total number of events                                         6                 21                    10                 37     
      NERVOUS SYSTEM DISORDERS                                                                                                           
        Total number of patients with at least one adverse event    7 (8.1%)          6 (8.3%)              3 (3.1%)          16 (6.3%)  
        HEADACHE                                                    7 (8.1%)          6 (8.3%)              3 (3.1%)          16 (6.3%)  
        Total number of events                                         8                 9                      4                 21     
      VASCULAR DISORDERS                                                                                                                 
        Total number of patients with at least one adverse event       0              1 (1.4%)                  0              1 (0.4%)  
        WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0              1 (0.4%)  
        Total number of events                                         0                 1                      0                 1      

# AET02 variant 3 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                                                                             
        High Level Term                                               Placebo     Xanomeline High Dose   Xanomeline Low Dose
          MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)       
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event       34 (39.5%)        61 (84.7%)            63 (65.6%)     
      Overall total number of events                                     71               189                    177        
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                
        Total number of patients with at least one adverse event     19 (22.1%)        34 (47.2%)            35 (36.5%)     
        Total number of events                                           37                86                    90         
        HLT_0778                                                                                                            
          Total number of patients with at least one adverse event    8 (9.3%)         26 (36.1%)            23 (24.0%)     
          Total number of events                                         11                38                    35         
          PRURITUS                                                    8 (9.3%)         26 (36.1%)            23 (24.0%)     
        HLT_0284                                                                                                            
          Total number of patients with at least one adverse event   9 (10.5%)         14 (19.4%)            15 (15.6%)     
          Total number of events                                         13                22                    24         
          ERYTHEMA                                                   9 (10.5%)         14 (19.4%)            15 (15.6%)     
        HLT_0762                                                                                                            
          Total number of patients with at least one adverse event    5 (5.8%)         11 (15.3%)            13 (13.5%)     
          Total number of events                                         9                 18                    18         
          RASH                                                        5 (5.8%)         11 (15.3%)            13 (13.5%)     
        HLT_0583                                                                                                            
          Total number of patients with at least one adverse event    3 (3.5%)          5 (6.9%)              6 (6.2%)      
          Total number of events                                         4                 8                     13         
          SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)              6 (6.2%)      
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                  
        Total number of patients with at least one adverse event     10 (11.6%)        29 (40.3%)            31 (32.3%)     
        Total number of events                                           20                72                    73         
        HLT_0317                                                                                                            
          Total number of patients with at least one adverse event    6 (7.0%)         21 (29.2%)            23 (24.0%)     
          Total number of events                                         10                34                    34         
          APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)            23 (24.0%)     
        HLT_0617                                                                                                            
          Total number of patients with at least one adverse event    3 (3.5%)         14 (19.4%)            13 (13.5%)     
          Total number of events                                         3                 22                    21         
          APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)            13 (13.5%)     
        HLT_0061                                                                                                            
          Total number of patients with at least one adverse event    3 (3.5%)         9 (12.5%)              9 (9.4%)      
          Total number of events                                         7                 16                    18         
          APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)              9 (9.4%)      
      GASTROINTESTINAL DISORDERS                                                                                            
        Total number of patients with at least one adverse event      4 (4.7%)         10 (13.9%)             6 (6.2%)      
        Total number of events                                           6                 21                    10         
        HLT_0016                                                                                                            
          Total number of patients with at least one adverse event    3 (3.5%)          6 (8.3%)              4 (4.2%)      
          Total number of events                                         3                 8                      5         
          VOMITING                                                    3 (3.5%)          6 (8.3%)              4 (4.2%)      
        HLT_0742                                                                                                            
          Total number of patients with at least one adverse event    3 (3.5%)          6 (8.3%)              3 (3.1%)      
          Total number of events                                         3                 13                     5         
          NAUSEA                                                      3 (3.5%)          6 (8.3%)              3 (3.1%)      
      NERVOUS SYSTEM DISORDERS                                                                                              
        Total number of patients with at least one adverse event      7 (8.1%)          6 (8.3%)              3 (3.1%)      
        Total number of events                                           8                 9                      4         
        HLT_0064                                                                                                            
          Total number of patients with at least one adverse event    7 (8.1%)          6 (8.3%)              3 (3.1%)      
          Total number of events                                         8                 9                      4         
          HEADACHE                                                    7 (8.1%)          6 (8.3%)              3 (3.1%)      
      VASCULAR DISORDERS                                                                                                    
        Total number of patients with at least one adverse event         0              1 (1.4%)                  0         
        Total number of events                                           0                 1                      0         
        HLT_0154                                                                                                            
          Total number of patients with at least one adverse event       0              1 (1.4%)                  0         
          Total number of events                                         0                 1                      0         
          WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0         

# AET02 variant 4 is produced correctly

    Code
      res
    Output
                                                                  Placebo     Xanomeline High Dose   Xanomeline Low Dose
      MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)       
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event   34 (39.5%)        61 (84.7%)            63 (65.6%)     
      Total number of events                                         71               189                    177        
      PRURITUS                                                    8 (9.3%)         26 (36.1%)            23 (24.0%)     
      APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)            23 (24.0%)     
      ERYTHEMA                                                   9 (10.5%)         14 (19.4%)            15 (15.6%)     
      APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)            13 (13.5%)     
      RASH                                                        5 (5.8%)         11 (15.3%)            13 (13.5%)     
      APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)              9 (9.4%)      
      HEADACHE                                                    7 (8.1%)          6 (8.3%)              3 (3.1%)      
      SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)              6 (6.2%)      
      VOMITING                                                    3 (3.5%)          6 (8.3%)              4 (4.2%)      
      NAUSEA                                                      3 (3.5%)          6 (8.3%)              3 (3.1%)      
      WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0         

# AET02 variant 5 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                     Placebo     Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)       
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event     34 (39.5%)        61 (84.7%)                 0         
      Overall total number of events                                   71               189                     0         
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                              
        Total number of patients with at least one adverse event   19 (22.1%)        34 (47.2%)                 0         
        Total number of events                                         37                86                     0         
        PRURITUS                                                    8 (9.3%)         26 (36.1%)                 0         
        ERYTHEMA                                                   9 (10.5%)         14 (19.4%)                 0         
        RASH                                                        5 (5.8%)         11 (15.3%)                 0         
        SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)                  0         
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                
        Total number of patients with at least one adverse event   10 (11.6%)        29 (40.3%)                 0         
        Total number of events                                         20                72                     0         
        APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)                 0         
        APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)                 0         
        APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)                  0         
      GASTROINTESTINAL DISORDERS                                                                                          
        Total number of patients with at least one adverse event    4 (4.7%)         10 (13.9%)                 0         
        Total number of events                                         6                 21                     0         
        NAUSEA                                                      3 (3.5%)          6 (8.3%)                  0         
        VOMITING                                                    3 (3.5%)          6 (8.3%)                  0         
      NERVOUS SYSTEM DISORDERS                                                                                            
        Total number of patients with at least one adverse event    7 (8.1%)          6 (8.3%)                  0         
        Total number of events                                         8                 9                      0         
        HEADACHE                                                    7 (8.1%)          6 (8.3%)                  0         
      VASCULAR DISORDERS                                                                                                  
        Total number of patients with at least one adverse event       0              1 (1.4%)                  0         
        Total number of events                                         0                 1                      0         
        WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0         

# AET02 variant 6 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
        SKIN IRRITATION                                      3 (3.5%)          5 (6.9%)              6 (6.2%)      
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        VOMITING                                             3 (3.5%)          6 (8.3%)              4 (4.2%)      
        NAUSEA                                               3 (3.5%)          6 (8.3%)              3 (3.1%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      

# AET02 variant 7 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                                                                    
        High Level Term                                       Placebo    Xanomeline High Dose   Xanomeline Low Dose
          MedDRA Preferred Term                               (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        HLT_0778                                                                                                   
          PRURITUS                                           8 (9.3%)         26 (36.1%)            23 (24.0%)     
        HLT_0284                                                                                                   
          ERYTHEMA                                           9 (10.5%)        14 (19.4%)            15 (15.6%)     
        HLT_0762                                                                                                   
          RASH                                               5 (5.8%)         11 (15.3%)            13 (13.5%)     
        HLT_0583                                                                                                   
          SKIN IRRITATION                                    3 (3.5%)          5 (6.9%)              6 (6.2%)      
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        HLT_0317                                                                                                   
          APPLICATION SITE PRURITUS                          6 (7.0%)         21 (29.2%)            23 (24.0%)     
        HLT_0617                                                                                                   
          APPLICATION SITE ERYTHEMA                          3 (3.5%)         14 (19.4%)            13 (13.5%)     
        HLT_0061                                                                                                   
          APPLICATION SITE IRRITATION                        3 (3.5%)         9 (12.5%)              9 (9.4%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        HLT_0016                                                                                                   
          VOMITING                                           3 (3.5%)          6 (8.3%)              4 (4.2%)      
        HLT_0742                                                                                                   
          NAUSEA                                             3 (3.5%)          6 (8.3%)              3 (3.1%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        HLT_0064                                                                                                   
          HEADACHE                                           7 (8.1%)          6 (8.3%)              3 (3.1%)      

# AET02 variant 8 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      

# AET02 variant 9 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
        SKIN IRRITATION                                      3 (3.5%)          5 (6.9%)              6 (6.2%)      
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        VOMITING                                             3 (3.5%)          6 (8.3%)              4 (4.2%)      
        NAUSEA                                               3 (3.5%)          6 (8.3%)              3 (3.1%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      

# AET02 variant 10 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        NAUSEA                                               3 (3.5%)          6 (8.3%)              3 (3.1%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      

# AET02 variant 11 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
      NERVOUS SYSTEM DISORDERS                                                                                     
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      

# AET02 variant 12 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      

